Zobrazeno 1 - 10
of 61
pro vyhledávání: '"S. Assadourian"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Remy Delva, Dorothée Semiond, J-Y Pierga, Véronique Girre, Alain Lortholary, Valérie Laurence, Véronique Diéras, S. Assadourian, Alain Livartowski
Publikováno v:
European Journal of Cancer. 49:25-34
Background Although the taxanes paclitaxel and docetaxel are among the most active agents for the treatment of a wide range of cancers, tumours often develop resistance to these treatments. Cabazitaxel is a novel taxane active in both preclinical mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf775b93223f67541ffbb0d6210b8fe
https://doi.org/10.1016/j.ejca.2012.07.008
https://doi.org/10.1016/j.ejca.2012.07.008
Autor:
Karen Soussan-Lazard, Nicolas Isambert, P Fumoleau, Gilles Freyer, Véronique Trillet-Lenoir, Benoit You, Sylvie Zanetta, Claire Falandry, S Assadourian, Samira Ziti-Ljajic, Laure Favier
Publikováno v:
British Journal of Cancer
Background: This phase I cohort study investigated aflibercept (vascular endothelial growth factor (VEGF) trap) plus docetaxel and cisplatin in patients with advanced solid tumours. Methods: Patients received intravenous aflibercept 4, 5, or 6 mg kg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecfcb0077e4e63aef8b85ee35f4a7d10
https://doi.org/10.1038/bjc.2012.304
https://doi.org/10.1038/bjc.2012.304
Autor:
Henri Roché, Pierre Fargeot, Jean-Paul Guastalla, Moïse Namer, Jacques Bonneterre, A Monnier, S Assadourian
Publikováno v:
British Journal of Cancer
This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy. One hundred and sevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7779f406d3f31685b25489c93aa09a6f
https://doi.org/10.1038/sj.bjc.6600645
https://doi.org/10.1038/sj.bjc.6600645
Autor:
Xavier Pivot, P. Koralewski, G. Schwartsmann, A. Chan, A. Gonçalves, J. L. Hidalgo, S. Assadourian, J. P. Lotz
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2008, 19 (9), pp.1547-52. ⟨10.1093/annonc/mdn171⟩
Annals of Oncology, Elsevier, 2008, 19 (9), pp.1547-52. ⟨10.1093/annonc/mdn171⟩
International audience; BACKGROUND: XRP6258 is a novel taxoid with a low affinity for P-glycoprotein. This multicenter phase II study assessed the activity of XRP6258 in the treatment of taxane-resistant metastatic breast cancer (MBC). PATIENTS AND M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60b9e62a2e21b4f6c88a545b140fc7c
https://www.hal.inserm.fr/inserm-00483407
https://www.hal.inserm.fr/inserm-00483407
Publikováno v:
Diabetes & Metabolism. 41:A121
Introduction La pompe a insuline est en majorite utilisee dans le traitement du diabete de type 1, chez les diabetiques de type 2 (DT2), son experience reste limitee. Nous avons realise une etude observationnelle, retrospective, chez des DT2 a 2 ans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66df87a160877b793cd831d41477531d
https://doi.org/10.1016/s1262-3636(15)30458-4
https://doi.org/10.1016/s1262-3636(15)30458-4
Autor:
M, Tubiana-Hulin, P, Beuzeboc, L, Mauriac, N, Barbet, M, Frenay, A, Monnier, J M, Pion, O, Switsers, J L, Misset, S, Assadourian, E, Bessa
Publikováno v:
Bulletin du cancer. 88(7)
One hundred forty-four patients with breast cancer and osteolytic bone metastases were randomized to receive either oral clodronate 1,600 mg/d (73 patients) or placebo (71 patients), in addition to either chemotherapy or hormonal therapy, for up to 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c8351d75fdf44609c5fa552bed7c8765
https://pubmed.ncbi.nlm.nih.gov/11495824
https://pubmed.ncbi.nlm.nih.gov/11495824
Publikováno v:
Diabetes & Metabolism. 39:A72
Introduction La maladie cardiovasculaire constitue la cause predominante de mortalite prematuree chez les diabetiques. En juin 2012, l’Agence Nationale de Securite du Medicament (ANSM) et la Haute Autorite de Sante (HAS) ont considere que le score
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08ca73aeefe3d9abd7aa8a16592ff3d6
https://doi.org/10.1016/s1262-3636(13)71922-0
https://doi.org/10.1016/s1262-3636(13)71922-0
Autor:
M. Bouhriba, B. Simion, S. Assadourian, M. Gros, F. Latil-Plat, E. Benamo, E. Auvry, M. Kadem
Publikováno v:
Diabetes & Metabolism. 39:A105
Introduction La prevalence du syndrome d’apnees obstructives du sommeil (SAOS) chez les patients diabetiques est importante. L’obesite, qui constitue le lit a la fois du diabete et du SAOS parait etre le denominateur commun. La severite du SAOS s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7f9fba573cacf8366be5ac57eaf2a65
https://doi.org/10.1016/s1262-3636(13)72069-x
https://doi.org/10.1016/s1262-3636(13)72069-x
Publikováno v:
Diabetes & Metabolism. 37:A97
Introduction Depuis ces deux dernieres annees, les agonistes du GLP-1 ont modifie le panorama therapeutique du diabetique de type 2. En plus de leur action hypoglycemiante, ces molecules ont des effets favorables sur la perte ponderale. Patients et m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9490e0e33ee31d5d0b969c9d61150c31
https://doi.org/10.1016/s1262-3636(11)70896-5
https://doi.org/10.1016/s1262-3636(11)70896-5